Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.
WSJ.com: Health, Wall Street Journal: Business: Health
Tue, 03/28/2017 - 6:44pm
Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.